ClinicalTrials.gg

TargetBeta

OPRK1

opioid receptor kappa 1 · also KOR, OPRK · Opioid receptors

8 programs in company-led studies act on OPRK1, from 8 companies: 4 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (7 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
NaltrexoneruleOrexigen Therapeuticsphase 4425 runningOPRD1, OPRM1ChEMBL
NalbuphineruleTrevi Therapeuticsphase 4203 runningOPRD1, OPRM1ChEMBL
nalmefeneruleH. Lundbeckphase 4201 runningOPRD1, OPRM1ChEMBL
cebranopadolruleTris Pharmaphase 3182 runningOPRD1, OPRL1, OPRM1, PNOCChEMBL
AticaprantruleJohnson & Johnsonphase 3131 running–ChEMBL
nalfurafineruleToray Industriesphase 391 running–ChEMBL
asimadolineruleTioga Pharmaceuticalsphase 361 running–ChEMBL
icalcaprantAbbViephase 262 running–the company's pipeline

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.